A Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in patients with ER-positive, HER2-negative locally advanced (recurrent or progressed) or metastatic breast cancer who have had previo

Condition: HER-positive, HER2-negative locally advanced (recurrent or progressed) or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitors (CDK4/6is) and endocrine therapy (ET).

Sponsor: Genetech_Roche

Phase:

A Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in patients with ER-positive, HER2-negative locally advanced (recurrent or progressed) or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitors (CDK4/6is) and endocrine therapy (ET).